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Text: Background and objective: Spinal cord atrophy occurs in multiple sclerosis (MS) and has been
proposed as a measure of neurodegeneration. The aim of this longitudinal study is to quantify spinal
cord atrophy to evaluate its association with clinical disability and other MRI measures.
Materials and methods: 31 patients (12 women; median age, 51 years; age range, [33, 61],
baseline EDSS median, 5.5; baseline EDSS range, [3, 6.5]) diagnosed of primary progressive MS,
underwent three serial 1.5 T brain and spinal cord MRI examinations (baseline, year 2, and year 7),
including the following sequences: PD/T2, 2D T1-weighted, and a spinal cord 3D magnetization
prepared rapid acquisition gradient echo (MPRAGE) T1-weighted. Spinal cord from C1 to C5 was
segmented in MRI scan using the spinal cord tool included in Jim 6.0. Using this method we
evaluated global cross-sectional spinal cord area (CSA), and CSA at C2-C3 (C23), C3-C4 (C34),
and C4-C5 (C45) levels. CSA measurements were then normalized (CSAn, C23n, C34n, C45n) to
the intra-cranial cross-sectional area measured at the inferior margins of the corpus callosum on an
axial slice of the proton density-weighted image of each subject. Percentage of change in spinal
cord measurements between baseline and 7th year exam were averaged per year of evolution. T2
lesion load (T2LL), T1 lesion load (T1LL), and brain parenchymal fraction (BPF) were measured at
each time point. EDSS was also evaluated as the area under the curve of EDSS values in each time
point normalized by the maximum area (AUCNEDSS). Partial correlations controlled for age and sex
were performed to evaluate the relationship between spinal cord measurements and radiological or
clinical measurements.
Results: All normalized CSA measurements showed moderate correlations with AUCNEDSS
ranging between -0.4872 and -0.3717 (p< 0.05). In addition, the mean annual percentage of change
in normalized CSA (pyCSAn: -0.7715%; pyC23n: -0.6155%; pyC34n: -0.7376%; pyC45n:
-0.7720%) showed significant correlations with baseline BPF (pyC23n vs. BPF: r=-0.4514, p=0.014;
pyC34n vs. BPF: r=-0.4556, p=0.013). Mean annual percentage of change in C34n also correlated
with BPF at year 2 (r=-0.3688, p=0.049).
Conclusions: Results suggest that development of spinal cord atrophy is associated with increasing
disability. Moreover, patients presenting larger baseline BPF seem to show a greater tendency for
future spinal cord atrophy development at some cervical levels.
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